Viral load monitoring for HIV

Last updated

Viral load monitoring for HIV is the regular measurement of the viral load of individual HIV-positive people as part of their personal plan for treatment of HIV/AIDS. [1] A count of the viral load is routine before the start of HIV treatment. [1]

Contents

Types

Various viral load tests might be used. One way to classify tests is by whether it is a nucleic acid test or non-nucleic acid test. [2] Variation in cost and the time it takes to get a result may be factors in selecting the type of test used. [3]

Uses

Viral load monitoring is used by HIV-positive people to develop a plan for their personal treatment of HIV/AIDS. [1]

A count of the viral load is routine before the start of HIV treatment. [1] If the treatment is not changed, then viral load is monitored with testing every 3–4 months to confirm a stable low viral load. [1] Patients who are medically stable and who have low viral load for two years may get viral load counts every 6 months instead of 3. [1] If a viral load count is not stable or sufficiently low, then that might be a reason to modify the HIV treatment. [1] If HIV treatment is changed, then the viral load should be tested 2–8 weeks later. [1]

Typical interpretation of results

Previous treatment guidelines recommended that anyone with a viral load greater than 100,000 copies/mL of blood should begin treatment. It is now standard of care in the United States to begin anti-retroviral treatment upon discovery of HIV positive status. HIV is a retrovirus, an RNA virus that enters a host cell and uses the host DNA replication machinery and the enzyme reverse transcriptase to produce DNA from the viral RNA genome. HIV also produces an integrase enzyme which is used to integrate the newly produced viral DNA into the host's DNA. The virus is then replicated every time the host cell's DNA replicates. Due to the nature of the virus the drugs used to treat HIV are called antiretroviral medicines, and the course of treatment is called antiretroviral therapy (ART). These potent medicines cannot cure an individual; they can however manage the virus and slow the progression of the HIV infection. Strict compliance with the prescribed ART regimen is vital to controlling the disease.[ citation needed ]

Highly active antiretroviral therapy (HAART) is the current recommended treatment for HIV. HAART entails taking a combination (regimen) of three or more ART medications from at least two different classes of drugs. There are six classes of ART medications: [ citation needed ]

Each class of medications uses a different mode of action to blocks the virus. Treatment is more effective in controlling the virus when a combination of medications from different classes is used. HAART also reduces the risk of developing drug resistance. Viral load tests are used to monitor the effects ART, to track viral suppression, and detect treatment failure. Successful combination ART should give a fall in viral load of 1.5 to 2 logs (30-100 fold) within six weeks, with the viral load falling below the limit of detection within four to six months. [4]

Laboratory monitoring schedule for patients using ART:

Initial Physician visitPrior to beginning ARTBeginning or modifying ART2 – 8 weeks after beginning or modifying ARTEvery 3 – 6 monthsEvery 6 – 12 monthsOther
Viral loadWhen entering into careEvery 3 – 6 monthsBaseline for comparisonRepeat every 4 – 8 weeks until viral load is suppressed to <200 copies/mL blood, then every 3 – 6 monthsIndividuals with a suppressed viral load, who are clinically & immunologically stable for more than 2 – 3 years, may go to every 6 monthsTreatment failure or when clinically indicated
CD4When entering into careEvery 3 – 6 monthsBaseline for comparisonRoutine monitoringIndividuals with a suppressed viral load, who are clinically stable, CD4 count monitoring may go to every 6 – 12 monthsTreatment failure or when clinically indicated

CD4 count indication

Viral load monitoring for HIV complements the CD4 count, which is another sort of test associated with monitoring HIV. Confusion about when to take a CD4 test is common. [1] The results of a viral load test help determine when a CD4 count is indicated. [1] CD4 cells are the primary target of HIV. A CD4 test quantifies Helper T cells and is often combined with viral load testing to monitor the progression of HIV. CD4 testing shows the strength of the immune system, but does not report viral activity. As established by the Centers for Disease Control and Prevention (CDC), a person with HIV and a CD4 count below 200 or a CD4 percentage below 14% is considered to have AIDS. [5] An increased CD4 count can result from an immune response to an infection or a recent vaccination. A decreased CD4 count, in combination with higher numbers on a viral load test, indicates an increased risk of getting sick from opportunistic diseases.[ citation needed ]

Blips in data

While receiving ART some patients with undetectable viral load measurements may experience an increase in viral load, to a low level (usually below 400 copies/mL blood), and then returned to an undetectable level. These transient blips do not indicate that the virus is developing resistance to drug therapy. Blips appear to be more common in the winter, suggesting a connection with illness such as colds and influenza. [6] Viral load blips are partially explained by various patient related factors, and thought to be relatively common. High level and sustained increases in viral load are frequently related to the development of drug resistance and/or viral mutations, and often dictate changes in ART.[ citation needed ]

Special populations

The window period for a test is the amount of time from the initial infection event until the disease can be detected. [7] Exposure to HIV, followed by replication of the virus, may take as long as six months to reach a level detectable in many testing methods. An HIV antibody test usually detects the HIV antibodies within two to eight weeks, but can have a valid negative result for a long as 2 to 6 months after initial infection. Viral load tests can also be used to diagnose HIV infection, especially in children under 18 months born to mothers with HIV, where the presence of maternal antibodies prevents the use of antibody-based (ELISA) diagnostic tests. [8] Pooled viral RNA testing shortens the window period to a median of 17 days (95% CI, 13-28 Days). [9] Although it is not the standard of care to use this test for diagnosis, in communities with high HIV prevalence, this test has a significantly improved negative predictive value over 3rd and 4th generation tests for detecting acute HIV infections. [10] [11]

Adverse effects

Safe sex practices are recommended for people with low viral load, just the same as for everyone else. [12] Researchers have questioned whether people who are told that they have a low viral load will respond to this information by lowering their use of safe sex practices. [12] As of 2010, further research might clarify the uncertainty around that idea. [12]

History

In January 2008, researchers from Switzerland published what would be termed the Swiss Statement, controversially arguing that HIV-positive individuals 1) on antiretroviral therapy, 2) with a viral load under 40 copies per mL, and 3) with no other sexually transmitted diseases themselves or in their partners could be assumed to not transmit the disease to healthy, HIV-negative partners. [13] Concerns were raised that blood-based measures of HIV viral concentrations at the time might not reflect actual viral counts in semen, and thus the Statement could encourage needlessly risky sexual practices, though the Statement authors argued they had taken this into account. [14]

On June 15, 2010, the FDA approved the first diagnostic test capable of detecting HIV antigens and HIV antibodies. The Abbott ARCHITECT HIV Ag/Ab combo test, a fourth-generation test, has an increased sensitivity for detecting infections during the acute phase (when compared to 1st and 3rd generation tests), when the immune system is still developing antibodies and the virus is replicating unchecked, and in one study, was able to detect 83% of such infections. [15]

Society and culture

A person, who may be unaware of the infection, is highly infectious during this time yet may test negative for HIV using tests that detect anti-HIV antibodies only. Although Nucleic Acid Amplification Testing NAAT is more expensive and can take a week for processing, some have argued that it may still be a preferred way to screen for HIV. [3]

Contagiousness

The higher the viral load value, the more viral elements there are in blood and other body fluids. For example, individuals with HIV are most contagious during the earliest (acute) stages of the infection, sometimes with millions of copies of HIV per centiliter of blood. According to one estimate, the majority of transmissions among gay men in the UK occur during primary infection. [16] This is because, at this phase, the immune response is still developing. Antibody levels against the virus during acute infection are often too low to be detected, meaning that an antibody test for a highly infectious individual can come back negative.[ citation needed ]

There is at least one documented case of an HIV-positive individual with an undetectable viral load infecting his partner. [17] Nevertheless, two recent major studies of serodiscordant couples in which the positive partner had an undetectable viral load have found no linked transmission events despite at least some unprotected sex among the couples. [18] [19] HPTN 052, a third study, found one linked transmission event in a test group of 886 couples, [20] although it is unclear whether the originally infected partner in this case had achieved an undetectable viral load at the time of transmission. [21]

Viral load in blood corresponds imperfectly to viral load in other parts of the body. Individuals with undetectable viral loads in their blood might not have undetectable viral loads in other bodily fluids, such as semen or vaginal secretions. In one recent study, of 83 men with undetectable viral loads, 21 had very slight but not undetectable viral loads in their semen. [22] However, it is unclear how much this actually increases transmission risk.[ citation needed ]

Distributors

Nucleic acid test

Nucleic acid tests are a typical way to measure viral load, including for HIV.

HIV NATs for viral load approved & licensed by the FDA for sale in the United States [23]
Test nameMolecular methodUseApprovedManufacturer
Roche Amplicor HIV-1 Monitor Test [24] PCR Viral load3/2/1999 Roche Molecular Systems, Inc. Pleasanton, CA
NucliSens HIV-1 QT [25] NASBA Viral load11/19/2001 bioMerieux, Inc Durham, NC
Trugene HIV-1 Genotyping Kit and Open Gene DNA Sequencing System [26] HIV-1 GenotypingPatient monitoring4/24/2002 Siemens Medical Solutions Diagnostics Berkeley, CA
ViroSeq HIV-1 Genotyping System with the 3700 Genetic Analyzer [27] HIV-1 GenotypingPatient monitoring6/11/2003 Celera Diagnostics Alameda, CA
Versant HIV-1 RNA 3.0 [28] bDNA Patient monitoring9/11/2002 Siemens Medical Solutions Diagnostics Berkeley, CA
Procleix Ultrio Assay [29] TMA (commercial variation of NASBA)

The three steps to the Procleix Ultrio Assay are done in one tube. [30] The first step is specimen preparation, the second is transcription-mediated amplification (TMA), and the third is a hybridization protection assay (HPA) using single-stranded complementary chemiluminescent labeled probes. A luminometer is used to measure the signal. The sensitivity of this assay is 98%.

Qualitative detection of HIV-1 RNA and hepatitis C virus (HCV) RNA from volunteer donors of whole blood and blood components, screen of live organ donors, and test blood specimens to screen cadaveric donors. HBV screening of individual samples and pooled samples.10/3/2006Gen-Probe San Diego, CA US Licence 1592 Chiron Corporation
Human Immunodeficiency Virus, Type 1 (HIV-1) Reverse Transcription (RT) Polymerase Chain Reaction (PCR) Assay [31] PCRQualitative detection of HIV-1 RNA in pools of human Source Plasma1/31/2007BioLife Plasma Services, L.P. Deerfield, IL US Licence 1640
Abbott RealTime HIV-1 Amplification Kit [32] RT-PCR

The sensitivity (linear range) for this assay is 40 copies/mL to 1010 copies/mL. Two probes are used. The HIV-1 probe is labeled with a fluorescent molecule and covalently binds to the 5' end. The second probe is a short oligonucleotide with a 3' end quencher molecule attached complementary to the 5' end of the HIV-1 probe. If the HIV-1 probe finds and attaches to a HIV target the quencher molecule is released and the resulting fluorescent emission is measured. The fluorescence is proportional to the log of the amount of virus in the sample.

Quantitation of HIV-15/11/2007 ABBOTT Molecular, Inc Des Plaines, IL
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test [33] PCR

Uses fluorescent resonance energy transfer (FRET) to enhance its automated RT-PCR. In the FRET reaction, a donor and acceptor probe exchange excitation energy when within 1-5 base pairs (bp) on the target sequences. The energy is emitted in the form of heat or fluorescence. The probes are designed to bind 1-5 bp from each other. The energy emission is proportional to the concentration of viral particles. The linear range for this assay is 48 copies/mL of blood.

Quantitation of HIV-15/11/2007 Roche Molecular Systems, Inc Pleasanton, CA

Non-nucleic acid-based tests

ExaVir™ Load Archived 2011-10-28 at the Wayback Machine Version 3 from Cavidi AB is a largely manual test, which has the European regulatory approval (CE-Mark) for clinical use and is also used for viral load monitoring. Virus-associated reverse transcriptase (RT) activity is measured and can therefore detect all types and subtypes of HIV. [2] The technology does not require sophisticated laboratories. [34] [35]

Related Research Articles

<span class="mw-page-title-main">HIV</span> Human retrovirus, cause of AIDS

The human immunodeficiency viruses (HIV) are two species of Lentivirus that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, the average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype.

<span class="mw-page-title-main">Zidovudine</span> Antiretroviral medication

Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

Viral load, also known as viral burden, is a numerical expression of the quantity of virus in a given volume of fluid, including biological and environmental specimens. It is not to be confused with viral titre or viral titer, which depends on the assay. When an assay for measuring the infective virus particle is done, viral titre often refers to the concentration of infectious viral particles, which is different from the total viral particles. Viral load is measured using body fluids sputum and blood plasma. As an example of environmental specimens, the viral load of norovirus can be determined from run-off water on garden produce. Norovirus has not only prolonged viral shedding and has the ability to survive in the environment but a minuscule infectious dose is required to produce infection in humans: less than 100 viral particles.

<span class="mw-page-title-main">Diagnosis of HIV/AIDS</span> Immunological test

HIV tests are used to detect the presence of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), in serum, saliva, or urine. Such tests may detect antibodies, antigens, or RNA.

The spread of HIV/AIDS has affected millions of people worldwide; AIDS is considered a pandemic. The World Health Organization (WHO) estimated that in 2016 there were 36.7 million people worldwide living with HIV/AIDS, with 1.8 million new HIV infections per year and 1 million deaths due to AIDS. Misconceptions about HIV and AIDS arise from several different sources, from simple ignorance and misunderstandings about scientific knowledge regarding HIV infections and the cause of AIDS to misinformation propagated by individuals and groups with ideological stances that deny a causative relationship between HIV infection and the development of AIDS. Below is a list and explanations of some common misconceptions and their rebuttals.

<span class="mw-page-title-main">Lamivudine</span> Chemical compound

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine, dolutegravir, and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

The Division of Acquired Immunodeficiency Syndrome (DAIDS) is a division of the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health. It was formed in 1986 as a part of the initiative to address the national research needs created by the advent and spread of the HIV/AIDS epidemic. Specifically, the Division's mission is to increase basic knowledge of the pathogenesis, natural history, and transmission of HIV disease and to support research that promotes progress in its detection, treatment, and prevention. DAIDS accomplishes this through planning, implementing, managing, and evaluating programs in (1) fundamental basic research, (2) discovery and development of therapies for HIV infection and its complications, and (3) discovery and development of vaccines and other prevention strategies.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

Infection with HIV, a retrovirus, can be managed with treatment but without treatment can lead to a spectrum of conditions including AIDS.

Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) co-infection is a multi-faceted, chronic condition that significantly impacts public health. According to the World Health Organization (WHO), 2 to 15% of those infected with HIV are also affected by HCV, increasing their risk of morbidity and mortality due to accelerated liver disease. The burden of co-infection is especially high in certain high-risk groups, such as intravenous drug users and men who have sex with men. These individuals who are HIV-positive are commonly co-infected with HCV due to shared routes of transmission including, but not limited to, exposure to HIV-positive blood, sexual intercourse, and passage of the Hepatitis C virus from mother to infant during childbirth.

HIV superinfection is a condition in which a person with an established human immunodeficiency virus infection acquires a second strain of HIV, often of a different subtype. These can form a recombinant strain that co-exists with the strain from the initial infection, as well from reinfection with a new virus strain, and may cause more rapid disease progression or carry multiple resistances to certain HIV medications.

Long-term nonprogressors (LTNPs), are individuals infected with HIV, who maintain a CD4 count greater than 500 without antiretroviral therapy with a detectable viral load. Many of these patients have been HIV positive for 30 years without progressing to the point of needing to take medication in order not to develop AIDS. They have been the subject of a great deal of research, since an understanding of their ability to control HIV infection may lead to the development of immune therapies or a therapeutic vaccine. The classification "Long-term non-progressor" is not permanent, because some patients in this category have gone on to develop AIDS.

<span class="mw-page-title-main">Rilpivirine</span> HIV treatment

Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.

The Berlin patient is an anonymous person from Berlin, Germany, who was described in 1998 as exhibiting prolonged "post-treatment control" of HIV viral load after HIV treatments were interrupted.

<span class="mw-page-title-main">HIV/AIDS research</span> Field of immunology research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.

HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.

Virological failure is defined as the failure to meet a specific target of antiviral drug treatment, namely the non-attainment or non-maintenance of undetectable viral load, particularly in the treatment of HIV. As antiretroviral therapy is evaluated by detecting the amount of copies of the virus in blood samples, the concept of virological failure gives a way to modify treatment of this disease.

Undetectable = Untransmittable (U=U) is a message used in HIV campaigns. It means that if someone has an undetectable viral load, they cannot sexually transmit HIV to others. U=U is supported by numerous health groups and organisations worldwide, including the World Health Organization (WHO). The validity of U=U has been proven through many clinical trials involving thousands of couples. U=U is also used as an HIV prevention strategy: if someone is undetectable, they can not pass it further and hence, prevents the virus from spreading. This is known as Treatment as Prevention (TasP).

References

  1. 1 2 3 4 5 6 7 8 9 10 HIV Medicine Association (February 2016), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIFoundation , HIV Medicine Association, retrieved 9 May 2016
  2. 1 2 Malmsten, Anders; Shao, Xing-Wu; Sjödahl, Staffan; Fredriksson, Eva-Lena; Pettersson, Ingvar; Leitner, Thomas; Källander, Clas F.R.; Sandström, Eric; Gronowitz, J. Simon (2005). "Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma". Journal of Medical Virology. 76 (3): 291–6. doi:10.1002/jmv.20360. PMID   15902697. S2CID   11551779.
  3. 1 2 Karris MY, Anderson CM, Morris SR, Smith DM, Little SJ; Anderson; Morris; Smith; Little (June 2012). "Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection". J. Clin. Microbiol. 50 (6): 1874–8. doi:10.1128/JCM.00106-12. PMC   3372146 . PMID   22442319.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ↑ DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 4, 2006. (available for download from AIDSInfo)
  5. ↑ U.S. Department of Health and Human Services. 2009. HIV and Its Treatment: What You Should Know. Available for download from https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf Archived 2015-05-14 at the Wayback Machine
  6. ↑ Carter M. (2008). Most viral load blips are short-lasting and of no significance. NAM Publications. Available at http://www.aidsmap.com/Most-viral-load-blips-are-short-lasting-and-of-no-significance/page/1430421/
  7. ↑ Testing Window Period. (2010). aids.gov. Available at http://aids.gov/hiv-aids-basics/prevention/your-hiv-status/testing-window-period/
  8. ↑ IV. The Challenge of Diagnosis. The United States President's Emergency Plan for Aids Relief. Available at http://www.pepfar.gov/progress/76907.htm
  9. ↑ Fiebig, E. W.; Wright, D. J.; Rawal, B. D.; Garrett, P. E.; Schumacher, R. T.; Peddada, L; Heldebrant, C; Smith, R; Conrad, A; Kleinman, S. H.; Busch, M. P. (2003). "Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection". AIDS. 17 (13): 1871–9. doi: 10.1097/00002030-200309050-00005 . PMID   12960819. S2CID   33073998.
  10. ↑ Patel, P.; MacKellar, D.; Simmons, P.; Uniyal, A.; Gallagher, K.; Bennett, B.; Sullivan, T. J.; Kowalski, A.; et al. (2010). "Detecting Acute Human Immunodeficiency Virus Infection Using 3 Different Screening Immunoassays and Nucleic Acid Amplification Testing for Human Immunodeficiency Virus RNA, 2006-2008". Archives of Internal Medicine. 170 (1): 66–74. doi:10.1001/archinternmed.2009.445. PMID   20065201. S2CID   28318217.
  11. ↑ Cohen, Myron S.; Gay, Cynthia L.; Busch, Michael P.; Hecht, Frederick M. (2010). "The Detection of Acute HIV Infection". The Journal of Infectious Diseases. 202 (S2): S270–7. doi: 10.1086/655651 . PMID   20846033.
  12. 1 2 3 Kalichman, Seth C.; Cherry, Chauncey; Amaral, Christina M.; Swetzes, Connie; Eaton, Lisa; Macy, Rene; Grebler, Tamar; Kalichman, Moira O. (2010). "Adherence to Antiretroviral Therapy and HIV Transmission Risks: Implications for Test-and-Treat Approaches to HIV Prevention". AIDS Patient Care and STDs. 24 (5): 271–277. doi:10.1089/apc.2009.0309. ISSN   1087-2914. PMC   2875951 . PMID   20438373.
  13. ↑ Vernazza, P; Bernard, EJ (29 January 2016). "HIV is not transmitted under fully suppressive therapy: The Swiss Statement – eight years later". Swiss Medical Weekly. 146: w14246. doi: 10.4414/smw.2016.14246 . PMID   26824882.
  14. ↑ Ballantyne, Coco (September 2008). "Math and semen analyses cast doubt on Swiss HIV stance". Nature Medicine. 14 (9): 896. doi: 10.1038/nm0908-896a . PMID   18776872.
  15. ↑ Chavez P, Wesolowski L, Patel P, Delaney K, Owen SM; Wesolowski; Patel; Delaney; Owen (December 2011). "Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay". J. Clin. Virol. 52 (Suppl 1): S51–5. doi:10.1016/j.jcv.2011.09.010. PMID   21983253.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ↑ Phillips, Andrew N; Cambiano, Valentina; Nakagawa, Fumiyo; Brown, Alison E; Lampe, Fiona; Rodger, Alison; Miners, Alec; Elford, Jonathan; Hart, Graham; Johnson, Anne M; Lundgren, Jens; Delpech, Valerie C (2013). "HIV & AIDS Information :: Viral load and the risk of transmission - Primary infection and sexual transmission". PLOS ONE. 8 (2): e55312. Bibcode:2013PLoSO...855312P. doi: 10.1371/journal.pone.0055312 . PMC   3574102 . PMID   23457467 . Retrieved 2015-02-01.
  17. ↑ Stürmer, M; Doerr, H. W.; Berger, A; Gute, P (2008). "Is transmission of HIV-1 in non-viraemic serodiscordant couples possible?". Antiviral Therapy. 13 (5): 729–32. doi: 10.1177/135965350801300513 . PMID   18771057. S2CID   23083658.
  18. ↑ Category: Treatment as Prevention. "CROI 2014: HIV Transmission through Condomless Sex [VIDEO]| Treatment as Prevention". hivandhepatitis.com. Retrieved 2015-02-01.
  19. ↑ Derek Thaczuk Published: 15 November 2006 (2006-11-15). "HIV & AIDS Information :: Spanish find that serodiscordant couples having unprotected sex to conceive - no cases of HIV transmission". Aidsmap.com. Retrieved 2015-02-01.{{cite web}}: CS1 maint: numeric names: authors list (link)
  20. ↑ Cohen, Myron S.; Chen, Ying Q.; McCauley, Marybeth; Gamble, Theresa; Hosseinipour, Mina C.; Kumarasamy, Nagalingeswaran; Hakim, James G.; Kumwenda, Johnstone; Grinsztejn, Beatriz; Pilotto, Jose H.S.; Godbole, Sheela V.; Mehendale, Sanjay; Chariyalertsak, Suwat; Santos, Breno R.; Mayer, Kenneth H.; Hoffman, Irving F.; Eshleman, Susan H.; Piwowar-Manning, Estelle; Wang, Lei; Makhema, Joseph; Mills, Lisa A.; De Bruyn, Guy; Sanne, Ian; Eron, Joseph; Gallant, Joel; Havlir, Diane; Swindells, Susan; Ribaudo, Heather; Elharrar, Vanessa; et al. (2011). "Prevention of HIV-1 Infection with Early Antiretroviral Therapy". New England Journal of Medicine. 365 (6): 493–505. doi:10.1056/nejmoa1105243. PMC   3200068 . PMID   21767103.
  21. ↑ ""Focusing specifically on the one HIV transmission that occurred in the immediate treatment group, Cohen noted that the HIV-negative partner tested positive for the virus—using standard Western blot testing—on day 85 of the study, whereas the HIV-positive partner's first undetectable viral load was documented 28 days after entering the study. The researchers believe that the HIV-negative partner was infected at least 50 days before testing positive, likely 84 to 190 days earlier. In other words, the HIV-negative partner was likely infected with the virus before the HIV-positive partner was able to achieve an undetectable viral load while on treatment."".[ permanent dead link ]
  22. ↑ "Top Stories : Undetectable Viral Load? Not Necessarily in Semen - by Tim Horn". Aidsmeds.com. 2012-04-03. Archived from the original on 2014-12-21. Retrieved 2015-02-01.
  23. ↑ Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays. US Food & Drug Administration. November 30, 2010. (available to download from https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM080466
  24. ↑ Consumer Affairs Branch (CBER) (2010-08-17). "Roche Amplicor HIV-1 Monitor Test". Fda.gov. Retrieved 2012-10-16.
  25. ↑ Consumer Affairs Branch (CBER). "NucliSens HIV-1 QT". Fda.gov. Retrieved 2012-10-16.
  26. ↑ "TRUGENE® HIV-1 Genotyping Kit and OpenGene® DNA Sequencing System- BK110007". Fda.gov. 2011-03-10. Retrieved 2012-10-16.
  27. ↑ "ViroSeq HIV-1 Genotyping System with the 3700 Genetic Analyzer". Fda.gov. Retrieved 2012-10-16.
  28. ↑ Consumer Affairs Branch (CBER). "VERSANT HIV-1 RNA 3.0 Assay (bDNA)". Fda.gov. Retrieved 2012-10-16.
  29. ↑ Consumer Affairs Branch (CBER). "Procleix Ultrio Plus Assay". Fda.gov. Retrieved 2012-10-16.
  30. ↑ Josko, D (2010). "Molecular virology in the clinical laboratory". Clinical Laboratory Science. 23 (4): 231–6. doi: 10.29074/ascls.23.4.231 . PMID   21140798. S2CID   19341821.
  31. ↑ "Human Immunodeficiency Virus, Type 1 (HIV-1) Reverse Transcription (RT) Polymerase Chain Reaction (PCR) Assay". Fda.gov. 2007-01-31. Retrieved 2012-10-16.
  32. ↑ Consumer Affairs Branch (CBER) (2009-02-18). "Abbott RealTime HIV-1 Amplification Reagent Kit, Abbott RealTime HIV-1 Calibrator Kit, Abbott RealTime HIV-1 Control Kit". Fda.gov. Retrieved 2012-10-16.
  33. ↑ Consumer Affairs Branch (CBER) (2009-02-19). "COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, 48 Tests; COBAS AmpliPrep/COBAS TaqMan Wash Reagent, 5.1 L". Fda.gov. Retrieved 2012-10-16.
  34. ↑ Greengrass, Vicki L.; Turnbull, Shannon P.; Hocking, Jane; Dunne, Amanda L.; Tachedjian, Gilda; Corrigan, Gary E.; Crowe, Suzanne M. (2005). "Evaluation of a Low Cost Reverse Transcriptase Assay for Plasma HIV-1 Viral Load Monitoring". Current HIV Research . 3 (2): 183–90. doi:10.2174/1570162053506955. PMID   15853722. Archived from the original on 2015-01-03. Retrieved 2016-05-26.
  35. ↑ Jennings, C.; Fiscus, S. A.; Crowe, S. M.; Danilovic, A. D.; Morack, R. J.; Scianna, S.; Cachafeiro, A.; Brambilla, D. J.; et al. (2005). "Comparison of Two Human Immunodeficiency Virus (HIV) RNA Surrogate Assays to the Standard HIV RNA Assay". Journal of Clinical Microbiology. 43 (12): 5950–6. doi:10.1128/JCM.43.12.5950-5956.2005. PMC   1317157 . PMID   16333081.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.